Mandate

Vinge advises Aspiro in capital raising

June 16, 2014

Aspiro AB (publ) has published a rights issue prospectus for approximately SEK 65.8 million before transactions costs. The rights issue is fully subscribed by, among others, the principal owner, Streaming Media AS, a company within the Schibsted group. The rights issue is intended to strengthen the company’s financial position and implement the company’s strategies.

Vinge advised Aspiro in connection with the rights issue. Vinge’s team primarily consisted of Jesper Schönbeck, Oskar Bellani and Amanda Granqvist.

Aspiro is a media technology company which is playing a prominent role in redefining music consumption. The company offers WiMP, a premium music streaming service for consumers with HiFi quality audio and the first and only multimedia service with integrated editorial, magazine and video content. In addition, Aspiro is also a content supplier to the media industry through the syndicated platform, RADR, and helps its partners to attract and retain visitors on their websites. For more information, visit www.aspiro.com.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026